timothy sykes logo
BIAF Stock Pops As Federal Deal Fuels Volatile Run Thumbnail
G Google News

BIAF Stock Pops As Federal Deal Fuels Volatile Run

TIM SYKES•UPDATED SEP. 1, 2026, 8:32 AM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

bioAffinity Technologies Inc. stocks have been trading up by 40.79 percent after promising cancer diagnostics news boosted investor optimism.

Key Takeaways Traders Need To Know

  • bioAffinity Technologies signed a nationwide federal healthcare distribution agreement with AvMEDICAL for its CyPath Lung noninvasive lung cancer diagnostic, providing access to VA and other federal healthcare systems through government-focused sales channels.
  • In Q2 2026, CyPath Lung test volume rose 216% year over year, physician accounts grew 122%, and existing customers increased orders by 71%, driving first-half CyPath Lung revenue up 159% to about $0.8M.
  • Total Q2 2026 revenue reached $1.5M, up 19% year over year, while EPS improved to -$0.64 from -$5.07, but bioAffinity Technologies remains deeply unprofitable.
  • As of 2026/06/30, bioAffinity held roughly $2.4M in cash after a $3.2M June equity raise and faces Nasdaq delisting risk, signaling dilution and execution pressure for BIAF.
  • The company is advancing a VA- and military-backed CyPath Lung trial and building a pipeline in asthma/COPD diagnostics and siRNA-based skin cancer therapeutics, extending BIAF’s longer-term story.

Candlestick Chart

Live Update At 08:32:16 EDT: On Tuesday, September 01, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 40.79%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

BIAF has turned into a classic high‑volatility, high‑risk biotech trading vehicle. On the chart, bioAffinity Technologies just went through a massive repricing: the stock traded around $0.40 in mid‑August, then pushed into the $5–$6 range and even spiked over $8 premarket. That kind of reverse‑split‑style move attracts momentum traders and short‑term scalpers more than long‑only funds.

Under the hood, BIAF’s business is still early stage. For Q2 2026, bioAffinity Technologies reported revenue of $1.5M, up from $1.27M a year earlier. That 19% growth rate is solid, but the base is tiny. EPS improved to -$0.64 from -$5.07, yet the company still lost roughly $3.4M in the quarter and burned more than $3.2M in operating cash.

More Breaking News

Key ratios back up the story of a company that sells a high‑margin product but lacks scale. Gross margin sits above 50%, but profit margins are sharply negative and returns on equity and assets are deeply in the red. BIAF’s current ratio near 1.4 shows some short‑term breathing room, but not comfort. For traders, this is a name driven by news and sentiment, not stable cash flows.

Why Traders Are Watching BIAF Right Now

BIAF jumped onto more watchlists after bioAffinity Technologies locked in a nationwide federal distribution agreement with AvMEDICAL for its CyPath Lung diagnostic. That deal opens doors into the Department of Veterans Affairs and other federal healthcare systems using AvMEDICAL’s government‑focused sales force and IDIQ contracting channels. For a micro‑cap with limited reach, this is a serious commercial upgrade.

The bull side of the BIAF trade leans heavily on that infrastructure shift plus real operating traction. In Q2 2026, CyPath Lung test volume surged 216% year over year. Physician accounts climbed 122%, and existing customers boosted orders by 71%. First‑half 2026 CyPath Lung revenue jumped 159% to about $0.8M. Those numbers tell traders something important: the product is not just a science project; doctors are actually using it more.

At the same time, total quarterly revenue of $1.5M shows CyPath Lung already drives the core of the BIAF story. The company is also running a VA‑ and military‑backed longitudinal clinical trial, which lines up nicely with the new federal access. Add an early pipeline in asthma/COPD precision diagnostics and topical siRNA‑based skin cancer therapies, and bioAffinity Technologies starts to look like a platform, not a one‑off test.

But traders cannot ignore the other side of the tape. As of 2026/06/30, bioAffinity had only about $2.4M in cash and needed a $3.2M equity raise in June just to shore up the balance sheet. BIAF also faces Nasdaq delisting risk. That combination means ongoing dilution and headline shocks remain on the table, which is exactly what fuels intraday spikes and dumps.

Conclusion

For active traders, BIAF is all about balancing big upside headlines with very real downside risk. On the positive side, bioAffinity Technologies now has a nationwide federal channel through AvMEDICAL, surging CyPath Lung utilization, and improving EPS trends. The VA and military‑backed trial plus a broader pipeline in respiratory and oncology diagnostics give BIAF some longer‑term optionality if management executes.

On the negative side, the numbers are clear. Revenue is still only $1.5M for the quarter, losses run in the multi‑million range, and cash at 2026/06/30 sat near $2.4M despite constant fundraising. Nasdaq delisting risk hangs over BIAF, and any future capital raise can hit the common stock hard. This is not a stable, cash‑rich business; it is a speculative biotech trying to scale.

That mix is exactly what draws momentum traders to bioAffinity Technologies. The huge swing from sub‑$1 to the $5–$8 zone shows how violent BIAF moves can be when news hits thin floats. As Tim Sykes likes to remind his community, “Volatile penny stocks can be great trading vehicles, but only if you respect the risk, cut losses quickly, and never believe the hype.” As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. For those studying the BIAF chart, that mindset applies every single day. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”